Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.68 |
| ▸ | IGF1R | P08069 | 4/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.68 |
| ▸ | KIT | P10721 | 4/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.68 |
| ▸ | FLT1 | P17948 | 4/20 | 0.68 |
| ▸ | FLT4 | P35916 | 4/20 | 0.68 |
| ▸ | TEK | Q02763 | 4/20 | 0.68 |
| ▸ | EGFR | P00533 | 3/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.68 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.67 |
| ▸ | CDK4 | P11802 | 4/20 | 0.60 |
| ▸ | CCND1 | P24385 | 4/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.60 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.60 |
| ▸ | CDK1 | P06493 | 2/20 | 0.60 |
| ▸ | PIM1 | P11309 | 2/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822950 | 0.93 | PRKCB (0.74) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL9085566 | 0.83 | CDK4 (0.74) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL12506684 | 0.83 | KDR (1.00) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL5429556 | 0.82 | GPR84 (0.62) | EGFRCCNB2CDK1PIM1CCNB1 | |
| SCHEMBL20624160 | 0.82 | CAMK2D (0.64) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL5879252 | 0.81 | PDGFRB (0.50) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL9085926 | 0.81 | CAMK2D (0.78) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL6259305 | 0.81 | EGFR (0.49) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL7824032 | 0.80 | CAMK2D (0.60) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL7815050 | 0.80 | PRKCB (0.60) | KDRIGF1RPDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0397060-B1 | Maleinimide derivatives and their use as medicines | GOEDECKE AG (DE) | 2001-11-21 | — | — | EP | claimed |
| US-5380746-A | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1995-01-10 | — | — | US | claimed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | claimed |
| US-11319320-B2 | PIM kinase inhibitor compositions, methods, and uses thereof | SNAP BIO, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200331914-A1 | PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF | SNAP BIO, INC. | 2020-10-22 | — | — | US | disclosed |
| EP-0397060-B1 | Maleinimide derivatives and their use as medicines | GOEDECKE AG (DE) | 2001-11-21 | — | — | EP | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5516915-A | Bis-(1H-indol-3-yl)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1996-05-14 | — | — | US | disclosed |
| US-5380746-A | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1995-01-10 | — | — | US | disclosed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331914-A1 | PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF | PIM1, PIM2, PIM3 | KDR 858/4885IGF1R 523/4885PDGFRB 765/4885 |
| US-11319320-B2 | PIM kinase inhibitor compositions, methods, and uses thereof | PIM1, PIM2, PIM3 | KDR 858/4885IGF1R 523/4885PDGFRB 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.